关键词: Guidelines Helicobacter pylori Italy Management

Mesh : Amoxicillin / therapeutic use Antacids / therapeutic use Anti-Bacterial Agents / therapeutic use Anti-Inflammatory Agents, Non-Steroidal / therapeutic use Antigens, Bacterial / analysis Barrett Esophagus / complications Bismuth / therapeutic use Breath Tests Clarithromycin / therapeutic use Disease Management Drug Therapy, Combination Dyspepsia / complications Feces Gastroesophageal Reflux / complications Helicobacter Infections / complications diagnosis drug therapy Helicobacter pylori Italy Levofloxacin / therapeutic use Metronidazole / therapeutic use Proton Pump Inhibitors / therapeutic use Stomach Neoplasms / prevention & control Urea

来  源:   DOI:10.1016/j.dld.2015.06.010   PDF(Sci-hub)

Abstract:
Knowledge on the role of Helicobacter pylori (HP) infection is continually evolving, and treatment is becoming more challenging due to increasing bacterial resistance. Since the management of HP infection is changing, an update of the national Italian guidelines delivered in 2007 was needed. In the III Working Group Consensus Report 2015, a panel of 17 experts from several Italian regions reviewed current evidence on different topics relating to HP infection. Four working groups examined the following topics: (1) \"open questions\" on HP diagnosis and treatment (focusing on dyspepsia, gastro-oesophageal reflux disease, non-steroidal anti-inflammatory drugs or aspirin use and extra-gastric diseases); (2) non-invasive and invasive diagnostic tests; (3) treatment of HP infection; (4) role of HP in the prevention of gastric cancer. Statements and recommendations were discussed and a consensus reached in a final plenary session held in February 2015 in Bologna. Recommendations are based on the best current evidence to help physicians manage HP infection in Italy. The guidelines have been endorsed by the Italian Society of Gastroenterology and the Italian Society of Digestive Endoscopy.
摘要:
暂无翻译
公众号